Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Jacob T. Lee

Goodwin Procter

main

Lee Jacob

Goodwin Associate Jacob Lee, from New York, practices in Business Law.

Jacob T. Lee

Areas of Practice

Credentials

Education

JD

BS

Admissions

Bars

Thought Leadership

Related Content

Approaching Effective Date for Regulation S-P Amendments: What Businesses Need to Know

Esports’ Surge Requires Navigating a Privacy Compliance Maze (Bloomberg Law)

Colorado Proposes Children’s Privacy Amendments to Privacy Act Regulations

Colorado Proposes Children’s Privacy Amendments to Privacy Act Regulations

In Updated Guidance on Use of Tracking Technologies by HIPAA Regulated Entities, HHS-OCR Takes Expansive View of When Information Related to Unauthenticated Individuals Is PHI

Massachusetts Proposes Sweeping Requirements for Processing Mobile Device Location Data

Goodwin Guides SpectrumAi in Acquisition by CentralReach

Health Data Regulation in Focus As 2025 State Legislative Session Comes to a Close (PLI Plus)

Goodwin Advises Later in Acquisition of Mavely

AlloVir and Kalaris Therapeutics to Merge

Goodwin Advises Septerna in $288 Million Upsized Initial Public Offering

Goodwin Advises MBX Biosciences in Upsized Initial Public Offering

Entrada Therapeutics Closes $100 Million Registered Direct Offering

Deciphera Pharmaceuticals Completes Its Sale to ONO Pharmaceutical For $2.4 Billion

Data, Privacy & Cybersecurity

Digital Health